Muscle Strength Training in Lower Limb Amputee Patients
Effects of Muscle Strength Training in Lower Limb Amputee Patients
This study is a clinical trial that evaluates the best treatment option using a strength training protocol and an endurance training protocol in patients with lower limb amputations who use prostheses. The protocol consists of 6 weeks of strength training and 6 weeks of endurance training, with a 1-month washout period between the two.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The assessments in this study focus primarily on strength, using a dynamometer and the 5 RM, functionality, using the AMP scale, mobility, using the TugTest, quality of life, using the WHOQOL-BREF, and perception of change, using the GROC.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gabriela B Dell´Elce
- Phone Number: +54 3462344478
- Email: gdellelce@ugr.edu.ar
Study Locations
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Recruiting
- Universidad del Gran Rosario
-
Contact:
- Gabriela B Dell´Elce, Pt
- Phone Number: 3462 344478
- Email: gdellelce@ugr.edu.ar
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with unilateral lower limb amputation
- Transtibial and/or transfemoral amputation
- Prosthetized
- Aged 18 to 75 years
- Who sign the informed consent form
Exclusion Criteria:
- That they are unable to complete the initial assessment
- That they undergo further secondary training
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Muscle strength training
Strength training lasts six weeks, during which submaximal strength percentages ranging from 75% to 90% are worked on. It is performed three times a week and follows a protocol consisting of progressive exercises for the large functional muscle groups relevant to the population being trained. |
Strength training lasts six weeks, during which submaximal strength percentages ranging from 75% to 90% are worked on. It is performed three times a week and follows a protocol consisting of progressive exercises for the large functional muscle groups relevant to the population being trained. |
|
Active Comparator: Endurance training
Resistance training will be carried out for 6 weeks, 3 times a week, with exercises prescribed by a protocol with training characteristics defined by bibliography found in the ACSM. |
Resistance training will be carried out for 6 weeks, 3 times a week, with exercises prescribed by a protocol with training characteristics defined by bibliography found in the ACSM. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Funcionality
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
It is assessed using the TUG test, which requires patients to get up from a chair, walk 3 meters, turn around, walk back to the chair, and sit down again. Patients will receive the following instructions: "Get up on the word 'go,' walk to the tape, turn around, walk back to the chair, and sit down." |
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
|
Changes in quality of life
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
It is assessed using a self-administered questionnaire called WHOQOL-BREF, which provides a profile of the person's perceived quality of life. |
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Maximum isometric muscle strength
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
It is evaluated using a dynamometer, in which three measurements are taken for each designated movement and the average of the maximum force and peak force is calculated. |
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
|
Changes on Movility
Time Frame: day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
It is assessed using the AMP functional rating scale (amputee mobility predictor). |
day 1, day 18 (last day of week 6), day 1 (after the wash out) and day 24.
|
|
Change in Global percepcion of change
Time Frame: assessments were performed at the end each protocol. day 18 and day 24
|
It is an assessment carried out using the Groc scale, which evaluates changes in perception. |
assessments were performed at the end each protocol. day 18 and day 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mauro S Barone, Ugr
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 619/2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
If necessary or required, informed consent and data analysis will be shared.
IPD Sharing Supporting Information Type
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.